| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Drug delivery means | US14741915 | 2015-06-17 | US10092516B2 | 2018-10-09 | Mary P. McCourt |
| The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of: cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate. | ||||||
| 2 | LYMPHOCYTE MEDIATED DELIVERY OF PROTEINS | US15301343 | 2015-04-15 | US20170182096A1 | 2017-06-29 | Robert Holt; Daniel Woodsworth |
| The invention is directed to methods and compositions for cell-based targeted delivery of predetermined compounds to a population of target cells. In some embodiments, methods of the invention include providing cytotoxic lymphocytes genetically modified to produce and sequester in lytic granules fusion proteins comprising a granzyme, or other effector agent, and a predetermined protein, so that upon specific contact of the cytotoxic lymphocytes with the target cells, the granzyme-perforin pathway of the cytotoxic lymphocytes is activated, leading to the delivery of the fusion protein to the cytosols of the target cells. | ||||||
| 3 | Fusion protein comprising granzyme B and use thereof | US14716275 | 2015-05-19 | US09724378B2 | 2017-08-08 | Jae Il Lee; Hye Yoon Kang; Dongkyu Shin; Jung Min Kim; Jungmin Lee |
| A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein. | ||||||
| 4 | Compositions and methods for treating amyotrophic lateral sclerosis | US14428765 | 2013-09-17 | US09539307B2 | 2017-01-10 | Brian Kaspar |
| The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis by decreasing the expression of a cytoplasmic granule toxin in astrocytes of a patient, or by increasing the expression of MHC class I in motor neurons of the patient. | ||||||
| 5 | Granzyme B protease variants | US14346600 | 2012-09-21 | US09528101B2 | 2016-12-27 | Stefan Barth; Sonja Schiffer; Grit Hehmann-Titt |
| The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer. | ||||||
| 6 | Drug delivery means | US11725831 | 2007-03-20 | US09119782B2 | 2015-09-01 | Mary P. McCourt |
| The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of: cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate. | ||||||
| 7 | 筋萎縮性側索硬化症の処置のための組成物および方法 | JP2015532145 | 2013-09-17 | JP2015529685A | 2015-10-08 | ブライアン・キャスパー |
| 本発明は、筋萎縮性側索硬化症の処置のための医薬組成物、キット、方法、および使用に関する。特に、本発明は、患者のアストロサイトにおける細胞質内毒性顆粒の発現を低減すること、または患者の運動ニューロンにおけるMHCクラスIの発現を増加させることによる、筋萎縮性側索硬化症の処置のための医薬組成物、キット、方法、および使用に関する。 | ||||||
| 8 | ジンセノサイドF1を有効成分として含む免疫増強用組成物 | JP2017049803 | 2017-03-15 | JP2017226642A | 2017-12-28 | キム、ソン チャン; キム、フン シク |
| 【課題】ナチュラルキラー細胞の脱顆粒活性を促進させ、細胞傷害活性を増進させ、細胞傷害因子の発現を増加させて、免疫増強剤として有用に使用することができる免疫増強用組成物を提供する。 【解決手段】本発明の免疫増強用組成物は、ジンセノサイドF1を有効成分として含む。 【選択図】図4a |
||||||
| 9 | 選択的細胞死誘発バイナリ−酵素系 | JP2015553106 | 2014-01-17 | JP2016510324A | 2016-04-07 | トウレル，シルファイン |
| 本発明は、ヒトおよび動物の癌および腫瘍の治療および/または治療における使用のための、選択的細胞死誘発バイナリ−酵素系を含有する混合製剤、方法、およびその使用に関する。 | ||||||
| 10 | COMPOSITION FOR ENHANCING IMMUNITY INCLUDING GINSENOSIDE F1 AS AN ACTIVE INGREDIENT | EP17161503.2 | 2017-03-17 | EP3260122A1 | 2017-12-27 | KIM, Sun Chang; KIM, Hun Sik |
The present invention relates to composition for enhancing immunity, comprising ginsenoside F1 as an active ingredient. Specifically, the composition according to the present invention promotes degranulation activity and cell-killing activity of natural killer cells, and increases expressions of cell-killing factors, thereby being effectively used as an immune enhancer.
|
||||||
| 11 | CYTOTOXIC MOLECULES RESPONSIVE TO INTRACELLULAR LIGANDS FOR SELECTIVE T CELL MEDIATED KILLING | EP15870819.8 | 2015-12-14 | EP3234120A1 | 2017-10-25 | CHEN, Yvonne Y.; HO, Patrick |
| Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities. | ||||||
| 12 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | EP13837504 | 2013-09-17 | EP2895606A4 | 2016-07-06 | KASPAR BRIAN |
| 13 | NOVEL SERINE PROTEASE VARIANTS | EP12775454.7 | 2012-09-21 | EP2758527B1 | 2016-11-09 | BARTH, Stefan; SCHIFFER, Sonja; HEHMANN-TITT, Grit |
| 14 | Anti-parasitic complexes | EP14182195.9 | 2014-08-26 | EP2990059A1 | 2016-03-02 | Fendel, Rolf; Kapelski, Stephanie; Barth, Stefan; Fischer, Rainer; Reimann, Andreas |
The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity. |
||||||
| 15 | NOVEL SERINE PROTEASE VARIANTS | EP12775454.7 | 2012-09-21 | EP2758527A2 | 2014-07-30 | BARTH, Stefan; SCHIFFER, Sonja; HEHMANN-TITT, Grit |
| The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer. | ||||||
| 16 | CYTOTOXIC MOLECULES RESPONSIVE TO INTRACELLULAR LIGANDS FOR SELECTIVE T CELL MEDIATED KILLING | EP15870819 | 2015-12-14 | EP3234120A4 | 2018-05-16 | CHEN YVONNE Y; HO PATRICK |
| Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities. | ||||||
| 17 | ANTI-PARASITIC COMPLEXES | EP15753943.8 | 2015-08-21 | EP3185906A1 | 2017-07-05 | FENDEL, Rolf; KAPELSKI, Stephanie; BARTH, Stefan; FISCHER, Rainer; REIMANN, Andreas |
| The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum ( P. falciparum ) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity. | ||||||
| 18 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | EP13837504.3 | 2013-09-17 | EP2895606A2 | 2015-07-22 | KASPAR, Brian |
| The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis by decreasing the expression of a cytoplasmic granule toxin in astrocytes of a patient, or by increasing the expression of MHC class I in motor neurons of the patient. | ||||||
| 19 | 그랜자임 B를 포함하는 융합 단백질 및 이의 용도 | KR1020150069912 | 2015-05-19 | KR1020150133157A | 2015-11-27 | 이재일; 강혜윤; 신동규; 김정민; 이정민 |
| 세포독성물질, 세포투과펩타이드 (cell penetrating peptide), 절단부위 (cleavage site), 및표적화부위 (targeting moiety)를포함하는융합단백질, 상기단백질을포함하는세포막투과용조성물, 및상기융합단백질을포함하는항암조성물이제공된다. | ||||||
| 20 | COMPOSITION FOR ENHANCING IMMUNITY INCLUDING GINSENOSIDE F1 AS AN ACTIVE INGREDIENT | US15461722 | 2017-03-17 | US20170368084A1 | 2017-12-28 | Sun Chang KIM; Hun Sik KIM |
| The present invention relates to composition for enhancing immunity, comprising ginsenoside F1 as an active ingredient. Specifically, the composition according to the present invention promotes degranulation activity and cell-killing activity of natural killer cells, and increases expressions of cell-killing factors, thereby being effectively used as an immune enhancer. | ||||||
QQ群二维码
意见反馈
意见反馈